查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751304

數位治療市場規模、佔有率、趨勢分析報告：按應用、最終用途、地區、細分市場預測，2025-2030 年

Digital Therapeutics Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By End Use (Patients, Providers, Payers, Employers), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

數位治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球數位治療市場規模預計到2030年將達到325億美元，2025年至2030年期間的複合年成長率為27.77%。

推動市場成長的主要因素是智慧型手機的廣泛普及。醫療服務提供者和患者能夠以可負擔的價格獲得數位醫療技術、對整合醫療系統的需求不斷成長以及以患者為中心的醫療服務是推動市場成長的關鍵因素。此外，全球化的加劇和生活方式的改變，例如吸菸率上升、營養不良、缺乏運動和飲酒消費量增加，也增加了罹患慢性病的可能性。

市場擴張主要得益於數位療法的日益普及以及美國食品藥物管理局（FDA）等主要監管機構的支持措施。例如，2020年4月，美國食品藥物管理局（FDA）發布了指南，旨在加強數位治療設備在精神疾病患者中的廣泛應用。此外，根據Kepios的數據，全球網路用戶的年成長率為7.6%，相當於每天新增約90萬網路用戶。儘管已開發國家和開發中國家的智慧型手機和網路使用率都很高，但非洲和南亞等地區仍面臨經濟制約，需要迎頭趕上。

慢性病盛行率的上升也推動了市場的成長。根據美國疾病管制與預防中心（CDC）下屬的國家慢性病預防與健康促進中心的數據，每10個美國成年人中就有6人患有慢性病，每10個成年人中就有4人患有兩種或兩種以上的慢性病。例如，Teladoc Health, Inc.於2022年2月推出了Chronic Care Complete，這是一款旨在改善醫療保健效果的慢性病管理解決方案。心血管疾病、癌症、糖尿病、慢性腎臟病、慢性肺病和阿茲海默症已被確定為美國死亡和殘疾的主要原因。

數位療法已成為治療各種健康狀況的重要選擇，這主要歸功於業界主要企業制定的客製化治療計劃和策略性舉措。這些措施包括併購、取得監管機構核准、推出新產品、建立夥伴關係等。此外，心血管疾病、糖尿病和焦慮症等慢性病的發生率不斷上升，促使市場主要參與者投資於數位治療解決方案。許多公司正在開發專注於焦慮管理的數位治療產品，其中許多產品處於不同的研發階段。這代表著巨大的市場成長機會。例如，2023 年 8 月，Welldoc 透露，其用於糖尿病管理的 BlueStar 數位健康解決方案已獲得第 10 次 FDA 510(k) 批准。此次批准將使 BlueStar 能夠將聯網的胰島素給藥資訊納入客製化的推注Bolus給藥建議中。

數位治療市場報告重點

  • 預計糖尿病領域將在 2024 年佔據市場主導地位，市場佔有率最大，為 29.75%，並在預測期內實現最快的複合年成長率。
  • 預計患者部門將在 2024 年佔據最大的市場佔有率，達到 34.50%，並在預測期內實現最快的成長率。
  • 北美數位治療產業佔據全球市場主導地位，2024 年的收益佔有率為 40.11%。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章數字治療市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 數位治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 數位治療市場：應用評估與趨勢分析

  • 2024年及2030年的市場佔有率
  • 細分儀表板
  • 全球數位治療市場前景
  • 糖尿病
  • 肥胖
  • 心血管疾病（CVD）
  • 呼吸系統疾病
  • 禁止抽煙
  • 中樞神經系統 (CNS) 疾病
  • 其他

第5章數位治療市場：最終用途估計與趨勢分析

  • 2024年及2030年的市場佔有率
  • 細分儀表板
  • 全球數位治療市場前景
  • 病人
  • 提供者
  • 付款人
  • 雇主
  • 其他

第6章 數位治療市場：區域估計和趨勢分析、按應用和最終用途

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2018 年至 2030 年：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 其他中東和非洲地區

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 公司簡介
    • OMADA HEALTH, INC.
    • Welldoc, Inc.
    • 2Morrow, Inc
    • Livongo Health, Inc.（Teladoc Health, Inc.）
    • Propeller Health（ResMed）
    • Fitbit LLC
    • Mango Health
    • CANARY HEALTH
    • Noom, Inc.
    • Pear Therapeutics, Inc.
    • Akili Interactive Labs, Inc.
    • HYGIEIA
    • DarioHealth Corp.
    • BigHealth
    • GAIA AG
    • Limbix Health, Inc.
Product Code: GVR-1-68038-768-1

Digital Therapeutics Market Growth & Trends:

The global digital therapeutics market size is estimated to reach USD 32.5 billion by 2030, registering to grow at a CAGR of 27.77% from 2025 to 2030 according to a new report by Grand View Research, Inc. The primary driver for expanding the market growth is the increased use of smartphones. The affordability of digital health technologies for healthcare providers & patients, rising demand for integrated healthcare systems, and care focusing on the patient are key factors fueling the market's growth. Furthermore, the growing globalization and shifts in lifestyle habits, such as higher rates of tobacco use, inadequate nutrition, insufficient physical activity, and rising alcohol consumption, increase the likelihood of chronic disease development.

The market's expansion is significantly influenced by the increasing adoption of digital therapeutics and the supportive initiatives by leading regulatory agencies such as the FDA. For instance, the U.S. FDA provided guidelines in April 2020 to enhance the reach of digital therapeutic devices for people suffering from psychiatric disorders. Furthermore, according to Kepios data, there's a 7.6% annual growth rate in the global internet user base, translating to around 900,000 new internet users daily. While developed and developing nations boast high smartphone and internet usage levels, areas such as Africa and South Asia need to catch up due to their economic limitations.

Increasing prevalence of chronic diseases is also driving the growth of the market. As per the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, while 4 out of 10 adults have two or more chronic diseases. For instance, in February 2022, Teladoc Health, Inc. launched Chronic Care Complete, a chronic condition management solution to improve healthcare outcomes. Cardiovascular diseases, cancer, diabetes, chronic kidney disease, chronic lung disease, and Alzheimer's have been identified as the leading causes of death and disability in the country.

Digital therapeutics have become an essential option for treating various health conditions, mainly due to customized treatment plans and strategic initiatives by leading companies in the industry. These actions include mergers and acquisitions, clearing regulatory approvals, introducing new products, and establishing partnerships. Moreover, the growing rates of chronic diseases such as cardiovascular disease, diabetes, and anxiety have driven critical players in the market to invest in digital solutions for treatment. Various companies are in the process of developing digital therapeutic products aimed specifically at managing anxiety, with many of these products in different phases of research and development. This presents a significant opportunity for market growth. For instance, In August 2023, Welldoc revealed it had obtained its 10th FDA 510(k) clearance for the BlueStar digital health solution for diabetes management. This clearance allows BlueStar to incorporate connected insulin dosing information into its customized recommendations for bolus insulin dosing.

Digital Therapeutics Market Report Highlights:

  • The diabetes segment dominated the market with largest market share of 29.75% in 2024 and is expected to register the fastest CAGR over the forecast period.
  • The patient segment held the largest market share of 34.50% in 2024 and is anticipated to register the fastest growth rate over the forecast period, owing to patients' rapid adoption of digital therapeutics.
  • North America digital therapeutics industry dominated globally with a revenue share of 40.11% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Application
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Digital Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Digital Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Digital Therapeutics Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Digital Therapeutics Market, by Application Outlook
  • 4.4. Diabetes
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Obesity
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Disease (CVD)
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Respiratory Diseases
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Smoking Cessation
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Central Nervous System (CNS) Disease
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Digital Therapeutics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Digital Therapeutics Market, by End Use Outlook
  • 5.4. Patients
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Providers
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Payers
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.7. Employers
    • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Digital Therapeutics Market: Regional Estimates & Trend Analysis, By Application, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Denmark
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Norway
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Rest of Europe
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/ reimbursement structure
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Rest of Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Rest of Asia Pacific
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/ reimbursement structure
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Rest of Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Rest of Latin America
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Rest of Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Rest of MEA
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework/ reimbursement structure
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Rest of MEA market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Company Profiles
    • 7.3.1. OMADA HEALTH, INC.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Welldoc, Inc.
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. 2Morrow, Inc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Livongo Health, Inc. (Teladoc Health, Inc.)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Propeller Health (ResMed)
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Fitbit LLC
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Mango Health
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. CANARY HEALTH
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Noom, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Pear Therapeutics, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Akili Interactive Labs, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. HYGIEIA
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. DarioHealth Corp.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. BigHealth
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. GAIA AG
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Limbix Health, Inc.
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviation
  • TABLE 3 North America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 4 North America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 5 North America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 7 U.S. macro dynamics
  • TABLE 8 U.S. digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 9 U.S. digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 10 Canada macro dynamics
  • TABLE 11 Canada digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 12 Canada digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 13 Mexico macro dynamics
  • TABLE 14 Mexico digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 15 Mexico digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 16 Europe digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 17 Europe digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 18 Europe digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 19 UK macro dynamics
  • TABLE 20 UK digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 21 UK digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 22 Germany macro dynamics
  • TABLE 23 Germany digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Germany digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 25 France macro dynamics
  • TABLE 26 France digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 27 France digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 28 Italy macro dynamics
  • TABLE 29 Italy digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 30 Italy digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 31 Spain macro dynamics
  • TABLE 32 Spain digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 33 Spain digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 34 Denmark macro dynamics
  • TABLE 35 Denmark digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 36 Denmark digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 37 Sweden macro dynamics
  • TABLE 38 Sweden digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 39 Sweden digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 40 Norway macro dynamics
  • TABLE 41 Norway digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 42 Norway digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 43 Asia Pacific digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 44 Asia Pacific digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 45 Asia Pacific digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 46 Asia Pacific digital therapeutics market estimates and forecasts, by therapeutic application, 2018 - 2030 (USD Million)
  • TABLE 47 Japan macro dynamics
  • TABLE 48 Japan digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 49 Japan digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 50 China macro dynamics
  • TABLE 51 China digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 52 China digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 53 India macro dynamics
  • TABLE 54 India digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 55 India digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 56 Australia Macro dynamics
  • TABLE 57 Australia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 58 Australia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 59 Thailand macro dynamics
  • TABLE 60 Thailand digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 61 Thailand digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 62 South Korea macro dynamics
  • TABLE 63 South Korea digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 64 South Korea digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 65 Latin America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 66 Latin America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 67 Latin America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 68 Brazil macro dynamics
  • TABLE 69 Brazil digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 70 Brazil digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 71 Argentina macro dynamics
  • TABLE 72 Argentina digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 73 Argentina digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 74 MEA digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • TABLE 75 MEA digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 76 MEA digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 77 South Africa macro dynamics
  • TABLE 78 South Africa digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 79 South Africa digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 80 Saudi Arabia Macro dynamics
  • TABLE 81 Saudi Arabia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 82 Saudi Arabia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 83 UAE Macro dynamics
  • TABLE 84 UAE digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 85 UAE digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 86 Kuwait Macro dynamics
  • TABLE 87 Kuwait digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 88 Kuwait digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • TABLE 89 Key company heat map analysis/company position analysis

List of Figures

  • FIG. 1 Market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Estimation methodology
  • FIG. 4 Data triangulation techniques
  • FIG. 5 Primary research pattern
  • FIG. 6 Market research approaches
  • FIG. 7 Value-chain-based sizing & forecasting
  • FIG. 8 QFD modeling for market share assessment
  • FIG. 9 Market formulation & validation
  • FIG. 10 Commodity flow analysis
  • FIG. 11 Digital therapeutics market snapshot, 2024 (USD Million)
  • FIG. 12 Segment snapshot
  • FIG. 13 Competitive landscape snapshot
  • FIG. 14 Parent market outlook
  • FIG. 15 Ancillary market outlook
  • FIG. 16 Digital Therapeutics market dynamics
  • FIG. 17 Digital therapeutics market driver impact
  • FIG. 18 Annual cost per person (USD) for key chronic conditions & by no. of co-morbidities
  • FIG. 19 Top countries by smartphone users, 2021
  • FIG. 20 Digital therapeutics market restraint impact
  • FIG. 21 Market participation categorization
  • FIG. 22 Market leaders and innovators
  • FIG. 23 Company market position analysis
  • FIG. 24 Major deals & strategic alliances analysis
  • FIG. 25 Digital therapeutics market: Application movement analysis
  • FIG. 26 Digital therapeutics Market: Application dashboard
  • FIG. 27 Global diabetes market, 2018 - 2030 (USD Million)
  • FIG. 28 Global obesity market, 2018- 2030 (USD Million)
  • FIG. 29 Global CVD market, 2018- 2030 (USD Million)
  • FIG. 30 Global respiratory diseases market, 2018 - 2030 (USD Million)
  • FIG. 31 Global smoking cessation market, 2018 - 2030 (USD Million)
  • FIG. 32 Global CNS diseases market, 2018- 2030 (USD Million)
  • FIG. 33 Global others market, 2018- 2030 (USD Million)
  • FIG. 34 Digital therapeutics market: End Use movement analysis
  • FIG. 35 Digital therapeutics market: End Use dashboard
  • FIG. 36 Global patients market, 2018- 2030 (USD Million)
  • FIG. 37 Global providers market, 2018 - 2030 (USD Million)
  • FIG. 38 Global payers market, 2018 - 2030 (USD Million)
  • FIG. 39 Global employers market, 2018 - 2030 (USD Million)
  • FIG. 40 Global other end uses market, 2018- 2030 (USD Million)
  • FIG. 41 Regional marketplace: Key takeaways
  • FIG. 42 North America: SWOT analysis
  • FIG. 43 North America digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 44 U.S. digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 45 Canada digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 45 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 46 Europe: SWOT analysis
  • FIG. 47 Europe digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 48 UK digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 49 Germany digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 50 France digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 51 Italy digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 52 Spain digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 53 Sweden digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 54 Norway digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 55 Denmark digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 56 Asia Pacific: SWOT analysis
  • FIG. 57 Asia Pacific Digital Therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 58 Japan digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 59 China digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 60 India digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 61 Australia digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 62 South Korea digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
  • FIG. 63 Thailand digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
  • FIG. 64 Latin America: SWOT analysis
  • FIG. 65 Latin America digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 66 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 67 Brazil digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 68 Argentina digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 69 Middle East and Africa: SWOT analysis
  • FIG. 70 Middle East and Africa digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 71 South Africa digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 72 Saudi Arabia digital therapeutics market, 2018 - 2030 (USD Million)
  • FIG. 73 UAE digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 74 Kuwait digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • FIG. 75 Heat map analysis
  • FIG. 76 List of key emerging companies/technology disruptors/innovators